Recombinant antigen NP (CTD) for SARS-CoV
NP (CTD) is the nucleoprotein C-terminal domain of the Coronavirus nucleocapsid (N). This recombinant antigen has been prepared by expressing aa 213 to 398 from de nucleoprotein of SARS-CoV. Coronavirus nucleocapsid (N) protein is a highly phosphorylated protein which not only is responsable for construction of the ribonucleoprotein complex by interacting with the viral genome and regulating the synthesis of viral RNA and protein, but also serves as a potent immunogen that induces humoral and cellular immunity. The nucleoprotein is one of the major antigens of the SARS-CoV and there are abundant antigenic sites predicted in this protein. Compared with other viral structural proteins, the low variation rate of the N protein with regards to its size suggests its importance to the survival of the virus.
This protein shows 92.5% identity with NP COVID-19.
Recombinant antigen for the diagnosis of Severe acute respiratory syndrome (SARS-2003) caused by SARS-CoV, a human infectious disease.
| SKU | Source | Applications | In-house validation | Details |
|---|---|---|---|---|
| RAG0080 | E. coli | WB, DB, IE, DE, CLIA, LF | ELISA |
|
* under availability, for liquid format
For research and comercial use IVD only (*)
(*) Our IVD reagents are provided for research and commercial use in vitro: not for human in vivo or therapeutic use. You can get more information about the general features and about the shipping, storage, defrost, manipulation and stability of all of our reagents. In addition, we follow a rigorous quality control for each lot.
Bact to list of Recombinant antigens for infectious diseases
How to reconsitute lyophizated vials
